BioMelbourne Network
Progressing BioIndustry
People on the Move
Members of the BioMelbourne Network are invited to contribute announcements regarding new appointments.
January 2010
After six years of heading up Medicines Australia's Health Policy and Research operations and three months as acting chief, Dr Brendan Shaw was named as the industry body's new Chief Executive.
October 2009
Professor Ian Gust succeeds Professor David Penington as Chairman of the Bio21 Cluster Board. Any correspondence related to the Bio21 Cluster Board should be addressed to him as such and sent to 157 Barry Street, Carlton 3053.
September 2009
Preclinical CRO, TetraQ Appoints K. Dyszynski to North America BD Position
Brisbane, QLD, Australia, 09 September 2009 – TetraQ, the commercial arm of The University of Queensland’s Centre for Integrated Preclinical Drug Development (CIPDD), has appointed Kris Dyszynski to the position of Business Development, North America.
As one of Australia’s leading preclinical contract research organisations (CRO’s), TetraQ (a registered business of UniQuest Pty Ltd) believes establishing a North American based development officer will help forge new business relationships and opportunities.
TetraQ CEO Maree Smith said the Queensland Smart State Entrepreneur-In- Residence Grant, worth $225,000 and announced recently by Treasurer Andrew Fraser, made the appointment possible.
“Mr Dyszynski’s new role will be undertaking business development activities for TetraQ within North America and identifying collaborative research and development activities for the CIPDD.”
“At TetraQ we sit in the translational research space; we assist universities, small biotech and pharmaceutical companies in getting potential drugs from the laboratory bench to the market,” she said.
“We perform preclinical drug trials, showing these drugs are efficacious – they do what the company says they do – and that they’re safe to go on to human trials.”
“This is a great opportunity for TetraQ and the CIPDD to establish a tangible presence within North America that further builds on TetraQ’s existing international reach and activities.”
Mr. Dyszynski has over 25 years of business experience in the biotechnology industry, with global responsibilities.
Prior to joining TetraQ, Mr. Dyszynski was based in the US as Vice President, Business Development for Australian company Alchemia Limited.
Mr Dyszynski said his new role gave TetraQ someone on the ground in North America, which enjoyed a significant proportion of the global R & D spend on preclinical development – worth almost $4 billion in 2008.
“There’s no real Australian Preclinical Contract Research Organisation (CRO) footprint in North America at present,” he said, “which means TetraQ can really make an impact.”
“TetraQ is at a distinct advantage in that it can offer an attractive value proposition for clients in North America by providing a high quality, good value, personalised service which is tailored to meet their specific needs.”
“So we have the opportunity here to bring a lot of preclinical drug development business into Australia.”
TetraQ expects the appointment will also facilitate knowledge diffusion between Mr. Dyszynski, who’s located in the US, and TetraQ and its other University of Queensland stakeholders, with further opportunities arising during his regular visits to Australia.
Media: Dean Simonsen (+61 7 33469933 or d.simonsen@tetraq.com.au)
August 2009
Sydney, Australia: Fluorotechnics Limited (ASX:FLS), global leader in fluorescence and protein technologies, has appointed Lars Utterman as a non-executive director. Mr Utterman has over 30 years sales and general management experience with biotechnology companies.
Currently, he is CEO of German-based IonGate Biosciences, a company specialising in developing systems for transporter protein measurements in drug discovery.
Mr Utterman is also Chairman of Cellectricon AB, Gyros AB and Ludesi AB, all in Sweden. He is also a member of the board of LIVC Technologies GmbH in Germany.
July 2009
Dr Bob Irving and Dr Jeanette Pritchard have moved from NanoVentures Australia to Quintain Consulting. www.quintainconsulting.com.au
Professor Doug Hilton is now the Director of The Walter & Eliza Hall Institute.
www.wehi.edu.au
Ms Julie Phillips (nee Nutting) has moved from Select Vaccines and is now the CEO for BioDiem Ltd.
www.biodiem.com
The Australian Stem Cell Centre has a new 5 year strategy and board.
www.stemcellcentre.edu.au
June 2009
Dr Ian Macreadie took up the role of Chief Science Officer at Sienna Cancer Diagnostics
www.siennadiagnostics.com.au
